Covid Vaccine Race

During a continuation of a difficult time in our history, overwhelmed providers need to take a step back and find time for themselves to unwind and destress from COVID-19.

Pfizer CEO Albert Bourla made the announcement in an interview.

New data suggests an additional “booster” dose of an mRNA COVID-19 vaccine is no longer just recommended but required for protection against the infectious Omicron variant.

Vaccine hesitancy is a significant hurdle experienced in the US. In response to this, a team of researchers analyzed adults who reported a medical provider recommended the COVID-19 vaccine, studied vaccination status, and general attitudes.

After increased awareness soon after the emergence of COVID-19, fewer Americans see plight of people of color.

The Advisory Committee on Immunization Practices (ACIP) voted yes to a third shot of the Pfizer-BioNTech COVID-19 vaccine in this pediatric population.

Novavax’s COVID-19 vaccine demonstrated 90.4% efficacy in a phase 3 trial with no moderate or severe cases reported among participants in the treatment group.

The FDA now recommends Americans 12 years and older receive COVID-19 booster shots. Additionally, they moved to shorten the time in between the second and third dose from 6 months to 5 for Pfizer-BioNTech recipients.

Investigators in the United Kingdom showed a Pfizer-BioNTech booster dose increases neutralizing antibodies in a laboratory setting, and Omicron might not be as damaging to the lungs as previous variants.

The fast-moving Omicron variant demonstrates a high transmissibility, but not as significant a hospitalization rate or mortality.

The US is on track to reach new records for 7-day average cases, though death rates remain lower.

A phase 3 trial shows one dose is 91.7 % effective against severe disease.

A study of mRNA vaccination in older people and people with comorbidities found vaccine efficacy of 69% against COVID-19 infection and 86% against death.

The administration is going to buy 500 million at-home rapid COVID-19 tests, and make them available to Americans. They also plan to use federal resources to provide pop-up clinics and get more pharmacists involved in vaccinations.

Two different doses of the company's mRNA vaccine were found to increase antibodies by up to 83-fold.

Planning travel and social gatherings as Omicron gathers steam requires extra preparation and a degree of flexibility.

Pfizer-BioNTech will be testing 3 doses of their vaccine in children older than 6 months and younger than 5 years, instead of the original 2-dose regimen.

The CDC is recommending the Pfizer-BioNTech and Moderna COVID-19 vaccines over Janssen’s, due to 57 cases of a rare blood clotting condition.

Side effects that occur during concurrent vaccine administrations can influence future vaccine decisions.

A review of the data and circumstances that led to authorization in children ages 5 to 11 years.

Clinical trial compares immunogenicity of mixing mRNA, adenoviral and spike-adjuvant vaccines in 2-dose series against COVID-19.

A reflection on the wins and setbacks in the second year of our pandemic, 2021.

A booster dose of the m-RNA vaccine reduced COVID-19 and the rates of severe illness across adult age groups.

New cohort data from VA medical centers provide more evidence of a correlate between antibody levels and vaccine effectiveness for mRNA vaccines.

An Israeli study found that a third “booster” shot of the Pfizer-BioNTech vaccine reduced the risk of COVID-19 death by 90%.

Faced with the growing threat of the Delta and Omicron variants, the FDA authorized Pfizer-BioNTech booster doses for 16- and 17-year-olds.

Data indicate that a third dose of the Pfizer-BioNTech vaccine, BNT162b2, increases the neutralizing antibody titers by 25-fold compared to 2 doses against the Omicron variant.

A study released tonight found 6 COVID-19 booster shots increased immunity for individuals who received a full 2 doses of the AstraZeneca or Pfizer-BioNTech vaccines.

The strategies address booster doses, travel, and rapid response.

As there is a lot of information regarding the Omicron variant, here is our latest slideshow to offer some insights on it.